Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Breast Neoplasms 4Neoplasm Metastasis 3Neoplasms 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Ovarian Neoplasms 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Breast Neoplasms, Male 1

Interventions

Magnetic Resonance Spectroscopy 10trametinib 7Nivolumab 7selpercatinib 6pembrolizumab 6dabrafenib 6Iodine-131 6Specimen Handling 5Biopsy 5lenvatinib 4Vemurafenib 4Iodine-124 4durvalumab 3cabozantinib 3binimetinib 3Ipilimumab 3Immunoglobulin G 3Fluorodeoxyglucose F18 3Disulfides 3Cyclophosphamide 3Cetuximab 3vandetanib 2ulixertinib 2omipalisib 2larotrectinib 2defactinib 2copanlisib 2cemiplimab 2anlotinib 2Watchful Waiting 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Neoplasms × Lapatinib × 1 year × Clear all
NCT01947023 2026-05-14

Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1 Active not recruiting
23 enrolled
Head & Neck

Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡